News

Researchers have shown that reprogramming T cells to target glioblastoma in mice resulted in control of these tumors.

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.

Genetic testing in metastatic non-small cell lung cancer (NSCLC) patients and subsequent molecular biomarker guided therapy is societally cost-effective compared to a chemotherapy treatment approach without molecular testing.

Patients with multiple sclerosis who received stem cell therapy instead of treatment with mitoxantrone achieved better outcomes over a 4-year-period.

Scientists are testing alternative therapeutic approaches that may delay disease progression and even protect and regenerate neurons.

An investigational cancer immunotherapy known as MPDL3280A (anti-PDL1) is receiving a breakthrough therapy designation from the US Food and Drug Administration (FDA) for treating non-small cell lung cancer (NSCLC).

For his efforts to prove that gene therapy could one day provide lasting control of IOP in patients with glaucoma with known genetic defects, Andras M. Komáromy, PhD, DVM, was awarded the 2015 Shaffer Prize for Innovative Glaucoma Research.

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

Treating patients with relapsing-remitting multiple sclerosis (RRMS) with autologous hematopoietic cell transplantation (HCT) has worked for most patients based on an interim report 3 years into a study. But the therapy has risks that critics say outweigh the benefits.

For children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

In this video from the 2014 ASH Meeting, Dr. Grupp discusses data from a trial using CAR T-cell therapy in children and young adults with relapsed, treatment-resistant ALL.

Early consolidation therapy with brentuximab vedotin after autologous stem cell transplant improved progression-free survival of patients with Hodgkin lymphoma.

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

The chimeric antigen receptor (CAR) T cell therapy JCAR015 has received a breakthrough therapy designation from the FDA as a treatment for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

Up until now, these treatments have not produced promising efficacy results in clinical trials. MRI could show the way.

In this edition of our ongoing series, the authors present two cases involving renal cell carcinoma patients treated with SBRT for pancreatic metastases.

Ninety percent of patients with relapsed/refractory acute lymphoblastic leukemia achieved complete remission after a T-cell therapy treatment targeting CD19.

Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.

The FDA granted breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 agent for the treatment of patients with non-small-cell lung cancer who do not have EGFR mutations or ALK rearrangements.

Stem cell therapy has gained increasing traction in various therapeutic areas, from cancer to diabetes to ocular regeneration.

Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma

The concept of targeting mitotic cell division to halt the progression of rapidly dividing cancer cells has long been a staple of oncology therapy, yet chemotherapy agents that are the prime examples of this approach are nonselective in their action and can kill normal and malignant cells alike.

A 71-year-old woman presented with back pain and was incidentally found to have a left upper pole renal mass. She underwent left open partial nephrectomy; the pathology results revealed a 2.2-cm clear-cell renal cell carcinoma (RCC) with negative margins and a Fuhrman nuclear grade of 2.